194 results on '"Kearns, W.G."'
Search Results
2. ESHRE PGD Consortium data collection V: Cycles from January to December 2002 with pregnancy follow-up to October 2003
3. The application of next generation sequencing (NGS) for clinical exomes within an in vitro fertilization (IVF) setting
4. Rate of mosaicism in 21,212 PGS embryos is < 5% by next generation sequencing (NGS)
5. The design and validation to amplify and detect the CCG repeats of the fragile X FMR1 gene by polymerase chain reaction of amplified embryonic DNA followed by fragment sizing on an applied biosystems Seq studio genetic analyzer
6. X chromosome sequencing in six women with pathologic diminished ovarian reserve: comparison of prioritization strategies
7. The impact of mitochondrial dna on embryo transfer outcomes
8. Enhanced bioinformatics and proprietary algorithms developed for next generation sequencing (NGS) can identify balanced translocations
9. Lower embryonal mitochondrial DNA content is associated with better quality embryos
10. Enhanced bioinformatics and propriety algorithms for next generation sequencing and chromosome analysis can identify ≤ 1 mb clinically significant deletions or duplications in preimplantation embryos
11. The incidence of deletions and duplications in preimplantation embryos as determined by enhanced next generation sequencing
12. The association between mitochondrial DNA content and implantation potential during IVF and preimplantation genetic screening cycles
13. Ploidy outcomes for day5 and 6 blastocysts analyzed by next generation sequencing for preimplantation genetic screening
14. In vitro fertilization (IVF) with 23-chromosome pair preimplantation genetic screening (PGS) from trophectoderm biopsy is more cost effective to achieve a live birth compared to IVF alone
15. Preimplantation genetic testing with array CGH and the transfer of euploid embryos does not decrease the rate of biochemical pregnancy after IVF
16. Blastocoel fluid (BF) harbors embryonic DNA that may result from the marginalization of aneuploid cells during embryogenesis
17. Ovarian reserve and the availability of at least one euploid embryo after preimplantation genetic screening
18. The potential use of blastocoel fluid (BF) from expanded blastocysts as a less invasive form of embryo biopsy for preimplantation genetic testing
19. All 23 chromosome pairs demonstrate a risk of aneuploidy when performing preimplantation genetic screening (PGS) on differentiated blastocysts
20. The use of next-generation sequencing (NGS) for preimplantation genetic screening (PGS) and diagnosis (PGD)
21. Comparative Genomic Hybridization Microarray (aCGH) Analysis of DNA Isolated from the Blastocoel Fluid from 26 Blastocysts
22. In vitro fertilization (IVF) with 23-chromosome pair preimplantation genetic screening (PGS) is cost effective to achieve a live birth compared to IVF alone for recurrent pregnancy loss (RPL)
23. Genetic normalization of differentiating aneuploid cleavage stage embryos
24. Two different microarray technologies for preimplantation genetic diagnosis (PGD) and screening (PGS), due to reciprocal translocation imbalances, demonstrate equivalent clinical pregnancy rates
25. The incidence of aneuploidy in differentiated blastocysts from patients with no prior first trimester spontaneous miscarriages or failed in vitro fertilization cycles
26. The first report of a viable, 31 week gestation pregnancy following the transfer of a genetically normalized blastocyst; embryo normalization can occur during differentiation to the blastocyst stage
27. Ovarian granulosa cells are a viable source of iPSCs with the capacity for epigenetically-biased differentiation into steroidogenic tissue of the ovary
28. Preimplantation genetic screening (PGS) on day-5 blastocysts with a day-6 embryo transfer results in a clinical pregnancy rate of 71%
29. I10 PGS/PGD evaluation of 7059 embryos from 872 in vitro fertilization (IVF) cycles using 23-chromosome single nucleotide polymorphism (SNP) or 23-chromosome comparative genomic hybridization (aCGH) microarrays
30. The majority of women undergoing preimplantation genetic screeining (PGS) using 23 chromosome single nucleotide polymorphism (SNP) microarrays will have euploid embryos available for uterine transfer
31. Aneuploid embryos as determined by 23 single nucleotide polymorphism (SNP) microarray preimplantation genetic screening (PGS) possess the potential to genetically normalize during early development
32. 23-chromosome single nucleotide polymorphism (SNP) microarray preimplantation genetic screening (PGS) for recurrent pregnancy loss (RPL) in 687 in vitro fertilization (IVF) cycles and 5871 embryos
33. All 23 Chromosomes have Significant Levels of Aneuploidy in Recurrent Pregnancy Loss Couples
34. The Incidence of Aneuploidy Significantly Increases After the Age of 40 in Women With a History of Recurrent Pregnancy Loss
35. Dense Single Nucleotide Polymorphism (SNP) Microarrays for the Identification of Aneuploidy and Consanguinity in Preimplantation Embryos
36. Evaluation of 571 In Vitro Fertilization (IVF) Cycels and 4,873 Embryos Using 23-Chromosome Single Nucleotide Polymorphism (SNP) Microarray Preimplantation Genetic Screening (PGS)
37. The Incidence of Aneuploidy Does not Significantly Increase With Advancing Paternal Age in Couples With A History of Recurrent Pregnancy Loss
38. Deletions and duplications identified by 23 chromosome single nucleotide polymorphism (SNP) microarray are associated with aneuploidy
39. 23-chromosome single nucleotide polymorphism (SNP) microarray preimplantation genetic screening (PGS) on blastocysts, versus day-3 embryos, results in significantly higher clinical pregnancy rates
40. The rate of de novo and inherited aneuploidy as determined by 23-chromosome single nucleotide polymorphism microarray (SNP) in embryos generated from parents with known chromosomal translocations
41. Chromosomal duplications (≥200 KILOBASES (KB)) are more common than deletions ≥200 KB in developing human embryos as identified by 23 chromosome single nucleotide polymorphism (SNP) microarray
42. 23-chromosome single nucleotide polymorphism (SNP) microarray detects genomic aberrations that may be missed by comparative genomic hybridization (CGH) arrays in preimplantation genetic screening (PGS)
43. Clinical results on single cells from 470 embryos using 23-chromosome single nucleotide polymorphism (SNP) microarray preimplantation genetic screening (PGS) from 45 patients
44. Improvement in diagnostic accuracy using single nucleotide polymorphism (SNP) microarrays versus fluorescence in situ hybridization (FISH) in preimplantation genetic screening (PGS) FOR ANEUPLOIDY
45. Single nucleotide polymorphism (SNP) microarray preimplantation genetic screening (PGS): a comparison between abnormal day-3 blastomeres and corresponding inner cell mass and trophectoderm cells
46. Validation of single nucleotide polymorphism (SNP) microarray PGD on single cell(s) from embryos
47. C32 Comprehensive microarray genetic analyses on single cell(s) from polar bodies or embryos to determine 23-chromosome aneuploidy, structural chromosome aberrations and genome-wide scans using single nucleotide polymorphisms (SNPs); to identify what partner provided the extra chromosome in aneuploid embryos; and to determine what embryo implanted following an in vitro fertilization (IVF) cycle
48. Comprehensive SNP microarray genetic analyses on single cell(s) from polar bodies or embryos to determine 23-chromosome aneuploidy, structural chromosome aberrations and complex genetic disorders
49. PGD on 3,189 embryos from 332 cycles due to parental reciprocal translocation, robertsonian translocations or pericentric inversions
50. SNP microarray genetic analyses to determine 23-chromosome ploidy, structural chromosome aberrations and genome-wide scans to identify disease risks from a single embryonic cell
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.